Nanoparticle‐Programmed Self‐Destructive Neural Stem Cells for Glioblastoma Targeting and Therapy

Patients with glioblastoma multiforme (GBM), the most common and aggressive form of adult brain cancer, suffer from poor outcomes, even after undergoing surgery or radiotherapy in conjunction with chemotherapy.[1] In the context of GBM treatment, nanoparticles offer the potential to improve drug delivery by increasing drug half-life and allowing for controlled release.[2] However, achieving extensive yet specific drug distribution in a tumor is still a major challenge for such systems, especially when targets including diffuse infiltrating cancer cells are distant from the site of administration. While diffusion-based delivery of these systems has been attempted, it often results in poor intratumoral distribution and an inability to reach distant metastatic sites.[3] Thus, in order to maximize the therapeutic potential of drug-nanoparticle conjugates while minimizing drug-related side effects, a targeted delivery strategy is needed to ensure that only malignant tissue in the brain is affected.